

IN THE CLAIMS

1.-13. (Previously Cancelled)

14. (Currently Amended) A pharmaceutical composition obtained from the green or mature whole fruit fruits of *Roystonea regia* comprising:

a mixture of primary fatty acids with 8 to 28 carbon atoms, the fatty acid selected from the group consisting of caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), miristic acid (C14:0), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid, and linolenic acid; and

a mixture of esters of the fatty acids;

wherein the fatty acids are enriched from ester hydrolysis.

15. (Currently Amended) The pharmaceutical composition according to claim 14 comprising:

Caprylic acid (C8:0)	< 3.0 % by wt.;
Capric acid (C10:0)	< 3.0 % by wt.;
Lauric acid (C12:0)	3.0 – 40.0 % by wt.;
Miristic acid (C14:0)	4.0 – 15.0 % by wt.;
Palmitic acid (C16:0)	10.0 – 80.0 % by wt.;
Palmitoleic acid (C16:1)	1.5 – 20.0 % by wt.;
Stearic acid (C18:0)	0.1 – 5.0 % by wt. and
Oleic acid (C18:1)	3.0 – 50.0 % by wt.

16. - 25. (Previously Cancelled)

26. (Withdrawn) A pharmaceutical composition for the treatment of BPH in a male mammal, said composition comprises; a *Roystonea regia* fruit extract comprising a mixture of fatty acids and their esters.

27. (Withdrawn) The pharmaceutical composition of claim 26, one of the fatty acids comprises palmitoleic acid in an amount of 1.5 to 20.0% by weight.

28. (Withdrawn) The pharmaceutical composition of claim 26, said fruit comprises a fresh fruit.

29. (Withdrawn) The pharmaceutical composition of claim 26, said fruit consists of the whole fruit.

30. (Withdrawn) A pharmaceutical composition for the treatment of BPH in a male mammal, said composition comprises:

 a *Roystonea regia* fruit extract comprising a mixture of fatty acids and their esters, one of the fatty acids comprises palmitoleic acid in an amount of 1.5 to 20.0% by weight; and wherein
 said fruit consists of the whole fruit.

31. (New) A pharmaceutical composition obtained from the green or mature whole fruit of *Roystonea regia* comprising:

a mixture of primary fatty acids with 8 to 28 carbon atoms, the fatty acid selected from the group consisting of caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), miristic acid (C14:0), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid, and linolenic acid, wherein the palmitic acid is present in amount of 10.0 – 80.0%, and the palmitoleic acid is present in an amount of 1.5 – 20.0%; and

a mixture of esters of the fatty acids wherein the fatty acids are enriched from ester hydrolysis.

32. (New) A pharmaceutical composition for treating BPH (benign prostatic hyperplasia) comprising an effective amount of a *Roystonea regia* extract wherein the extract is obtained by the process of:

- i) drying green or mature fruits of *Roystonea regia*;
- ii) grinding the dried fruit into a powder;
- iii) subjecting the powder to alkaline hydrolysis; and
- iv) extracting the hydrolysed powder with an organic solvent, whereby the extract comprises a mixture of primary fatty acids with 8 to 28 carbon atoms, wherein the fatty acids comprise caprylic acid (C8:0) in an amount of <3.0%, capric acid (C10:0) in an amount of <3.0%, lauric acid (C12:0) in an amount of 3.0-40.0%, miristic acid (C14:0) in an amount of 4.0-15.0%, palmitic acid (C16:0), in an amount of 10.0-80.0%, palmitoleic acid (C16:1) in an amount of 1.5-

20.0%, stearic acid (C18:0) in an amount of 0.1-5.0% and oleic acid (C18:1) in an amount of 3.0-50.0%.